RETATRUTIDE 16MG
16mg · 2ml vial · 16 weeks (dose dependent)
Retatrutide is an advanced, once-weekly injectable peptide that activates three key metabolic pathways — GLP-1, GIP, and glucagon receptors — to accelerate fat loss, enhance insulin sensitivity, and improve metabolic efficiency.
Often described as the "next-generation GLP-1," it optimizes glucose control while uniquely boosting energy expenditure and lean-mass preservation.
Physical label displays 4mg/0.5ml in a 2ml vial size, for a total content of 16mg.
Medical compliance
All medications are physician-prescribed following individual evaluation and dispensed by US-licensed 503A compounding pharmacies. Statements have not been evaluated by the FDA. Information on this page is for educational purposes only and is not a substitute for professional medical advice. Use only under qualified medical supervision.